Steroid sulfatase (STS) is responsible for the hydrolysis of aryl and alkyl steroid sulfates and has a pivotal role in regulating the formation of biologically active estrogens. STS may be considered a new promising drug target for treating estrogen-mediated carcinogenesis. However, the molecular mechanism of STS expression is not well-known. To investigate whether tumor necrosis factor ( 
Introduction
Steroid sulfatase (STS) is the enzyme responsible for the hydrolysis of steroid sulfates such as estrone sulfate (E1S) and dehydroepiandrosterone sulfate (DHEAS) to their unconjugated, biologically active forms (Reed et al., 2005) . Plasma concentrations of E1S or DHEAS are 10-20 times higher than those of the unconjugated forms and the half-life of steroid sulfates (10-12 h) is also much longer than of unconjugated steroids (30-40 min) (Ruder et al., 1972) . E1S is considered an important source for the formation of active estrogens which is able to be produced by STS action. The gene for human STS is located on the distal short arm of the X-chromosome and maps to Xp22.3-Xpter. The gene consists of 10 exons and spans 146 kb, with the intron sizes ranging from 102 bp up to 35 kb (Reed et al., 2005) . STS is mainly found in steroidogenic and steroid-responsive tissues such as placenta, prostate, testis, ovary, breast, and adrenal gland although tissue distribution of STS is believed to be ubiquitous in small quantities. The functional importance of STS is underlined by X-linked ichthyosis, one of the most prevalent human skin genetic diseases, which is associated with the germ line mutation of STS (Stein et al., 1989; Hernández-Martín et al., 1999) .
Metabolic activation of E1S has been suggested to be a major factor in mammary carcinogenesis. STS is responsible for the formation of active estrogens such as estrone (E1) or 17β-estradiol (E2) that can stimulate tumor growth (Reed et al., 2005) . Moreover, STS expression is increased in malignant breast tumors and has prognostic importance (Dao et al., 1974; 10, 20 or 40 ng/ml) for 18 h. Total RNA was isolated and expression of STS mRNA was assessed using RT-PCR. Expression of GAPDH mRNA was determined as RNA control. For Western blot, total cellular lysates were prepared and STS protein expression was assessed by STS antibody. GAPDH was used as a loading control. (B) Cells were incubated at 37 o C with TNF-α (40 ng/ml) for various time intervals. Expression of STS mRNA was assessed using RT-PCR and real-time PCR analysis. The data shown represent the fold increase in the levels of STS mRNA relative to the control after normalization with GAPDH mRNA level. *P ＜ 0.05 compared with the control cells. The protein levels of STS were determined by Western blot analysis.
1986; Naitoh et al., 1989; Utsumi et al., 2000) . STS activity is approximately 50 times greater in both premenopausal and postmenopausal breast tumors compared to normal breast tissues (Pasqualini et al., 1996) . Because of the postulated significant role of STS on carcinogenicity of estrogens, STS is regarded as a target enzyme for blocking estrogen-mediated carcinogenesis and potent STS inhibitors have been developed and tested in rodents and in postmenopausal women with breast cancer (Purohit et al., 1995; Malini et al., 2000; Stanway et al., 2006; Foster et al., 2008) . Although STS expression is mainly considered significant in breast and endometrial cancers, results of another study also suggest the significance of STS expression for estrogen production in human prostate cancer (Selcer et al., 2002) .
Although expression and activity of STS is increased in malignant tumors, little is known about the regulation of STS expression. Previous reports indicated that tumor necrosis factor-alpha (TNF-α) increases STS activity in breast cancer cells (Purohit et al., 1996; Newman et al., 2000) .
In these studies, we explored the effect of TNF-α on STS expression in PC-3 human prostate cancer cells to elucidate whether TNF-α is able to regulate transcription of the STS gene. As TNF-α induces cell survival signals through activation of the PI 3-kinase and its downstream target Akt (Khwaja, 1999; Ozes et al., 1999; Zhou et al., 2000a) , evidence for the involvement of PI 3-kinase/Akt signal pathway in STS expression by TNF-α has also been determined.
Results
To determine whether TNF-α regulates STS gene expression in PC3 cells, the mRNA and protein expression of STS were measured by RT-PCR and Western blot, respectively. PC-3 cells were grown for 18 h in the presence of increasing concentrations of TNF-α. TNF-α increased STS mRNA expression in a concentration-dependent manner ( Figure 1A ). In agreement with increasing mRNA levels, levels of STS protein were also significantly induced by TNF-α ( Figure 1A) . We compared the time courses for the induction of STS mRNA and protein expression in TNF-α-treated cells ( Figure 1B ). The induction of STS mRNA was shown after 3 h of treatment with TNF-α (40 ng/ml) and the expression of STS mRNA had increased -5 fold and -9 fold by 24 h and 48 h after addition of TNF-α ( Figure  1B) .
To explore the molecular basis for TNF-α-induced STS expression, we tested various inhibitors for signal transduction pathways such as LY294002 (PI 3-kinase inhibitor), MG132 (proteasome inhibitor and NF-κB blocker), SB203580 (p38 MAPK inhibitor), or PD168393 (EGFR tyrosine kinase inhibitor). Cells were pretreated with LY294002 (20 μM), MG132 (1 μM), SB203580 (1 μM) or PD168393 (2 μM) or DMSO vehicle for 30 min and then stimulated with 40 ng/ml TNF-α for 18 h. Expression of STS mRNA was assessed using RT-PCR. Figure 2A showed that TNF-α increased STS mRNA and that this induction was almost completely prevented following treatment with LY294002 or MG132. However, neither SB203580 nor PD168393 attenuated TNF-α-induced STS expression. In (PD) for 30 min before incubation with 40 ng/ml of TNF-α for 18 h. Total RNA was isolated and expression of STS mRNA was assessed using RT-PCR. Expression of GAPDH mRNA was determined as RNA control. The intensities of the PCR products were quantified using a densitometer. The bar graph was obtained by calculating the percentages of the intensity of each PCR products of STS gene relative to GAPDH controls, defined as 100%. The experiments were carried out in triplicates. *P ＜ 0.05 compared with the TNF-α only-treated cells. (B) Cells were pretreated with 20 μM LY294002 for 30 min and then incubated with 40 ng/ml of TNF-α for 18 h. Total cellular lysates were prepared and STS protein expression was determined by Western blot analysis. GAPDH was used as a loading control. (C) Cells were preincubated with 20 μM LY294002 for 30 min before incubation with TNF-α (40 ng/ml) for 18 h. Cells were fixed and incubated with STS antibody. Cells were then stained with Alexa Fluor 594-labeled secondary antibody and fluorescence was determined by fluorescence microscopy. addition, STS protein expression induced by TNF-α was significantly suppressed by LY294002 pretreatment ( Figure 2B ). Expression of STS was also investigated by immunofluorescence staining with an antibody against human steroid sulfatase. As shown in Figure 2C , TNF-α strongly stimulated STS expression in PC-3 cells determined by immunofluorescence analysis and pretreatment with LY294002 for 30 min almost completely blocked TNF-α-induced STS expression ( Figure  2C ). These data indicates that the PI 3-kinase/Akt pathway may be involved in STS gene expression by TNF-α.
To study whether TNF-α induces STS expression through a pathway that involves the PI 3-kinase/ Akt pathway, the pharmacological inhibitors of PI 3-kinase/Akt were utilized ( Figure 3A) . All of the PI 3-kinase/Akt inhibitors such as LY294002 (PI 3-kinase inhibitor, 20 μM), wortmannin (PI 3-kinase inhibitor, 10 μM), or Akt inhibitor IV (10 μM) blocked STS mRNA expression by TNF-α. Since TNF-α has been found to activate PI 3-kinase/Akt pathway in various cells (Ozes et al., 1999; Madge and Pober, 2000) , we determined the effect of TNF-α on phosphorylation of Akt on Ser-473. As shown in Figure 3B , an increase in Akt phosphorylation was observed at 18 h following TNF-α treatment (40 ng/ml) in association with increased STS level. To determine if activation of the PI 3-kinase/Akt pathway by TNF-α is required for STS induction, we carried out experiments with a dominant negative plasmid against Akt. When cells were transfected with the plasmid for dominant negative Akt (DN-Akt), phosphorylation of Akt on Ser-473 o C with TNF-α (40 ng/ml) for 18 h. Total RNA was isolated and expression of STS mRNA was assessed using RT-PCR. Expression of GAPDH mRNA was determined as RNA control.
was almost completely blocked and TNF-α-induced STS expression also decreased to the control level ( Figure 3B ). To confirm that Akt phosphorylation is required for STS gene expression, the plasmid for a constitutively active form of Akt1 (Myr-Akt1) was transiently transfected into PC-3 cells and the status of Akt phosphorylation (on Ser-473) and STS expression were examined after 48 h ( Figure  3C ). We found that enhanced Akt phosphorylation on Ser-473 by myristoylated Akt1 transfection increased STS expression.
To determine whether induction of STS mRNA expression by TNF-α is limited only to PC-3 prostate cancer cells, we used three additional cancer cell lines. In addition to PC-3 (androgen-independent prostate cancer cell), LNCaP (androgen-dependent prostate cancer cell), MDA-MB-231 (estrogenindependent breast cancer cell), or MCF-7 cells (estrogen-dependent breast cancer cell) were incubated with TNF-α (40 ng/ml) for 18 h. In agreement with results for the PC-3 cells, the three different cancer cell lines also showed induction of STS mRNA by TNF-α (Figure 4 ).
Discussion
Because steroids such as estrogens play a key role in the development of hormone-dependent cancers, understanding biosynthetic mechanisms and related enzymes is important. Because E1S is considered a reserved form of estrogens in cells, the interest in the STS that initiates the generation of E1 from E1S rose to identify a target enzyme for blocking hormone-related tumor formation.
Although the roles of STS on E2-related carcinogenesis have been studied mainly in breast cancer cells, STS may also control the formation of estrogens from E1S in prostate cancer cells. STS has been found in 85% of malignant prostate cancer tissue but absent in the normal tissues (Nakamura et al., 2006) .
Previous studies have reported that inflammatory cytokines such as TNF-α, interleukin-6 (IL-6), and interleukin-1β (IL-1β) exist at high concentrations in mammary tumor cells and stimulate STS activity (Purohit et al., 1996; Newman et al., 2000) . In MCF-7 cells, TNF-α (7.5 ng/ml) increased the activity of steroid sulfatase by 116 % compared with untreated cells (Purohit et al., 1996) . Moreover, STS mRNA expression in breast tumor-derived fibroblasts was approximately 2.4-fold higher than in fibroblasts from proximal tissues (Newman et al., 2000) . Although TNF-α increases the activity of STS in MCF-7 cells, molecular mechanisms of STS expression by TNF-α are not completely understood yet.
In this study, we demonstrated whether human STS gene expression might be controlled by TNF-α. Our data clearly show that TNF-α is able to induce STS mRNA expression in PC-3 cells in a concentration and time-dependent manner. A previous report indicated that the ability of TNF-α to increase STS activity in MCF-7 cells might result from a post-transcriptional effect (Newman et al., 2000) . Thus, we suggest that transcriptional control is also important for STS expression as well as post-transcriptional regulation.
We observed that the PI 3-kinase/Akt pathway positively regulated TNF-α-induced STS gene expression because PI 3-kinase inhibitors (LY294002 and wortmannin), or Akt inhibitor (Akt inhibitor IV) suppressed STS mRNA expression by TNF-α. The importance of Akt in TNF-α-induced STS expression is confirmed by the observation that downregulation of Akt by dominant-negative Akt effectively suppressed STS induction by TNF-α and that overexpression of myristoylated Akt1 increased STS gene expression. These results suggest that Akt activation is essential for TNF-α-mediated STS expression.
Akt has been identified as a key regulator of the survival signaling pathways mediated by growth factors and cytokines, which exerts antiapoptotic effects (Kennedy et al., 1997; Zhou et al., 2000b; Lawlor and Alessi, 2001 ). Several studies have implicated that Akt is overexpressed in various tumor types including prostate and breast cancers (Nakatani et al., 1999) . Furthermore, TNF-α has been found to stimulate the phosphorylation of Akt and this phosphorylation is dependent on PI 3-kinase activation (Madge and Pober, 2000; Radeff-Huang et al., 2007) . Therefore, it is likely that the ability of TNF-α to induce STS expression is mediated by PI 3-kinase/Akt activation.
Akt inhibitor IV is a cell-permeable benzimidazole compound that inhibits Akt phosphorylation by targeting the ATP binding site of a kinase upstream of Akt but it does not affect PI 3-kinase activity. Akt inhibitor IV is known to strongly inhibit phosphorylation of Ser-473 for Akt1. Data from our study with Akt inhibitor IV indicate that the phosphorylation of Akt on Ser-473 may be necessary for the TNF-α effect. Moreover, decreased phosphorylation of Akt on Ser-473 by dominant-negative Akt prevents TNF-α to induce STS expression and enhanced phosphorylation of Ser-473 by the activated form of Akt stimulates STS expression.
The mammalian target of rapamycin (mTOR) is a member of the phosphatidylinositol kinase-related kinase family that assembles into two functionally distinct complexes such as mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) (Feldman et al., 2005) . Akt stimulates mTORC1 to directly phosphorylate the ribosomal S6 kinases and the eIF4E-binding proteins. mTORC2 is comprised of mTOR, Rictor, mSIN1 and mLST8 and the best-characterized function of mTORC2 is in the phosphorylation of Akt on Ser-473 (Sarbassov et al., 2005; Wullschleger et al., 2006) . Because our data strongly suggest that Akt signaling may actively participate in STS expression, the possibility that the involvement of mTOR as a downstream effector of Akt in the mechanism of TNF-α-induced STS expression needs to be elucidated.
In this article, we showed that the proteasome inhibitor MG-132 (1 μM) significantly suppressed TNF-α-induced STS mRNA (Figure 2A ). Because MG-132 is able to inhibit NF-κB activity by preventing the proteasomal degradation of IκBα, NF-κB signaling pathway may also play an important role in STS gene expression by TNF-α. Previous report indicated that 1α,25-dihydrovitamin D 3 stimulates steroid sulfatase activity through NF-κB pathway in myeloid leukemic cells such as HL-60 and THP-1 (Hughes et al., 2008) . Because NF-κB signaling pathway may control STS gene expression by TNF-α as well as 1α,25-dihydrovitamin D 3 , it will be necessary to determine what mechanism is involved in this event. Recently, we found that insulin-like growth factor II (IGF-II), which is known to activate NF-κB pathway, is able to induce STS gene expression in PC-3 cells and the proteasome inhibitors such as MG-132 and bortezomib completely prevented IGF-II-mediated STS mRNA expression (data not shown).
The ability of TNF-α to induce STS expression is not limited to PC-3 cells, because we found that TNF-α also increases STS mRNA expression in LNCaP, MDA-MB-231, and MCF-7 cells. There are three mammalian isoforms of Akt, which are Akt1, Akt2, and Akt3. Nakatani et al. (1999) demonstrate that Akt1 and Akt3 were present in PC-3 cells, whereas little Akt3 was found in LNCaP cells. Similarly, Akt1 and Akt3 were present in MDA-MB-231 cells, while only Akt1 was detected in MCF-7 cells by Western blotting. Our results that TNF-α is able to induce STS expression in all these cancer cell lines suggest that Akt1 is likely to mediate TNF-α-induced STS expression.
In conclusion, the present findings indicate that TNF-α-mediated induction of human STS occurs by transcriptional activation via a mechanism involving PI 3-kinase/Akt pathway in human prostate cancer cells as well as in human mammary cancer cells. Induction of STS gene expression by inflammatory cytokines such as TNF-α has profound implications on estrogen-mediated carcinogenesis.
Methods

Reagents
Human recombinant TNF-α was purchased from PeproTech (Rocky Hill, NJ). RPMI 1640 medium, penicillin or streptomycin were obtained from Welgene (Daegu, Korea). Fetal bovine serum (FBS) or enhanced chemiluminescence detecting reagent was purchased from Thermo Fisher Scientific (Rockford, IL). LY294002, MG132, PD168393, and Akt inhibitor-IV were obtained from Calbiochem (San Diego, CA). SB203580 was obtained from Tocris (Bristol, UK). Wortmannin was obtained from Enzo Life Science (Plymouth Meeting, PA). Maloney murine leukemia virus (M-MLV) reverse transcriptase or RNase inhibitor (RNasin) was purchased from Promega (Madison, WI). Taq DNA polymerase was obtained from TaKaRa Bio (Shiga, Japan). Goat polyclonal antibodies for STS or HRP-conjugated mouse anti-goat IgG were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Alexa Fluor Ⓡ 594-conjugated donkey anti-goat IgG was from Invitrogen (Eugene, OR). Other chemicals and reagents were of the highest grade commercially available.
Cell culture
Cell lines were obtained from American Type Culture Collection (ATCC, Manassa, VA) and cultured in RPMI 1640 medium supplemented with 10% (v/v) heat-inactivated FBS, 100 unit/ml penicillin, and 100 μg/ml streptomycin. Cells were maintained at 37 o C in a humidified atmosphere of 5% CO2.
RT-PCR and quantitative real-time PCR
Total RNA was extracted using RNeasy Mini Kit (Qiagen, Valencia, CA). Total RNA (500 ng) was transcribed at 37 o C for 1 h in a volume of 20 μl containing 5 × RT buffer, 10 mM dNTPs, 40 units of RNase inhibitor, 200 units of M-MLV reverse transcriptase, and 100 pmole of oligo-dT primer. Subsequently, 0.8 μl of the reaction mixture from each samples was amplified with 10 pmole of each oligonucleotide primers, 0.2 mM dNTPs, 1.5 mM MgCl2 and 1.25 units of Taq DNA polymerase in a final volume of 25 μl. PCR was performed as follows: One cycle of 95 o C for 2 min, followed by 35 cycles of denaturation at 95 o C for 10 s, annealing at 61 o C for 15 s, and extension at 72 o C for 15 s. Human STS cDNA was amplified using a sense primer (5'-CCTCCTACTGTTCTTT CTGTGGG-3') and an antisense primer (5'-GGTCGATATT GGGAGTCCTGATA-3'). Human GAPDH was amplified using a sense primer (5'-TGAACGGGAAGCTCACTGG-3') and an antisense primer (5'-TCCACCACCCTGTTGCTGT A-3'). The number of amplification cycles was optimized in preliminary experiments to ensure that the PCR did not reach a plateau. PCR products were subjected to a 2% (w/v) agarose gel electrophoresis, and analyzed by ChemiDoc XRS (Bio-Rad, Hercules, CA). Real-time PCR was performed using SYBR Ⓡ Premix Ex Taq (Takara) and the MyiQ2 Two-Color Real-Time PCR detection system (Bio-Rad). The PCR analyses for human STS was done as follows: after an initial denaturation at 95 o C for 10 min, the amplification was done by denaturation at 95 o C for 10 s, annealing at 58 o C for 15 s, and extension at 72 o C for 15 s for 40 cycles.
Western blot
Cells were solubilized with ice-cold lysis buffer (pH 7.4) containing 25 mM HEPES, 1% Triton X-100, 50 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM PMSF, and 1 μg/ml leupeptin. Extracted proteins (30 μg) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on 10% polyacrylamide gels, and were electrophoretically transferred onto polyvinylidene difluoride (PVDF) membrane. Membranes were blocked in 5 % (w/v) nonfat dried milk in Tris-buffered saline for 2 h at 4 o C. Membranes were then incubated overnight with anti-STS polyclonal antibodies as a 1:500 dilution in 5 % (w/v) nonfat dried milk in Tris-buffered saline containing 0.1% Tween-20. The membrane was incubated with a horseradish peroxidase (HRP)-conjugated goat anti-goat IgG antibody. Proteins were visualized by an enhanced chemiluminescence method and the band intensity was analyzed by ChemiDoc XRS densitometer and quantified by Quantity One software (Bio-Rad). Protein concentrations were estimated using the bichinchoninic acid method according to the supplier's recommendation (Thermo) using bovine serum albumin as a standard.
Transient transfection
For transient transfection, cells were transfected with WelFect-EX transfection reagent (Welgene) using pECE myr-Akt-HA or kinase-deficient dominant-negative pCMV6-Akt-K179M mutant plasmids as recommended by the manufacturer. Briefly, one day prior to transfection, approximately 5 × 10 5 cells per 60 mm-plate were seeded in RPMI 1640 medium containing 10% FBS. Cells were washed in PBS and then resuspended in Opti-MEM serum free medium. Transfection was carried out with 3 μg of plasmid DNA and 12.5 μl of transfection reagent for 5 h at 37 o C. After transfection, cells were maintained in RPMI medium containing 10% FBS for 36 h.
Immunofluorescence staining
Cells grown on coverslips were treated for 18 h with TNF-α in RPMI 1640 medium with 10% FBS, rapidly washed with PBS, then fixed with 3.7% (w/v) paraformaldehyde in phosphate buffer containing 0.1 M sodium phosphate, pH 7.4, for 30 min at room temperature. After washing with PBS, the cells were blocked for 15 min in PBS containing 5% donkey serum and 0.2% Triton X-100, then incubated with anti-STS antibody (1:500) for 1 h, washed extensively, and stained for 1 h with Alexa Fluor 594-labeled donkey anti-goat IgG antibody (1:1000). After further washes, the coverslips were mounted on glass slides using Ultra Cruz Mounting Medium (Santa Cruz). Fluorescence signals were analyzed on a DM 2500 fluorescence microscope (Leica, Wetzlar, Germany).
Data analysis
Statistical analysis was performed by using one-way analysis of variance, followed by Dunnett's pairwise multiple comparison t-test with GraphPad Prism software (GraphPad Software Inc., San Diego, CA) when appropriate. The difference was considered statistically significant at P ＜ 0.05.
